- The company can grow efficiently; as revenue grows, the Cost of Revenue and SG&A expenses as a % of revenue decrease. Management expects this trend to continue.
- According to The National Eye Institute, over 24 million Americans are affected by cataracts. The market potential allows the company to grow further.
- The key shareholder of the company has recently been actively increasing its stake. The company is trading at a significant discount to its fair price.
- We are bullish on the company.
For further details see:
Harrow Health: Good Opportunity For Growth Investors